Not exact matches
Nagrath, director of Rice's Laboratory for Systems Biology of Human Diseases, said the new metabolic
analysis indicates that ovarian cancer may be susceptible to multidrug cocktails, particularly if the amounts of the drugs can be tailored to match the metabolic
profile of a patient's
tumor.
Utilizing
tumors from a genomic
analysis clinical trial at Rutgers Cancer Institute examining rare cancers and those that respond poorly to standard care, 97
tumors with the P13K / AKT / mTOR pathway were
profiled.
Previously, genetic counselors tested a small number of genes sequentially based on family
profile and
tumor analysis until the culprit was identified.
Individual
profiles based on the
analysis of each patient's
tumor cells revealed clinically relevant information that could be used to prioritize the drugs most likely to be effective in these cases.
Many of our brain
tumor clinical trials include
analysis of the molecular
profiles of patients»
tumors.
In the next decade, molecular research is going to further develop along five lines: predictive medicine, that investigates the genetic conditions predisposing to
tumor risk; early molecular diagnosis; the evaluation of each patient's prognosis based on his / her genetic
profile, in other words, the
analysis of what kind of mutation affects the DNA of altered cells; the investigation of the individual response to drugs, based on our genetic knowledge; «smart drugs», molecules able to hit the target in a selective way, killing only the deprogrammed cells.»
To further confirm the alteration of DDX3 expression in cancer specimens, the expression
profiles of DDX3 were examined in normal -
tumor paired HCC samples by immunohistochemical staining
analysis using specific anti-DDX3 antibody.
Because DDX3 harbors growth - suppressive ability and transcriptional modulation activity of the p21waf1 / cip1 promoter, in this work we further examined the deregulated expression of DDX3 in
tumors by a cancer
profiling array and immunohistochemical staining
analysis.
Our groundbreaking Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing on the genetic
analysis of pediatric cancer patients including in children with malignant brain
tumors, and determines whether targeted treatments may be available based upon their personalized
tumor genomic sequencing
profiles.